Study #2025-0164
CD4CAR T cell therapy for CMML
MD Anderson Study Status
Enrolling
Treatment Agent
CD4CAR
Description
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Myelomonocytic Leukemia
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.